GlycA: A composite nuclear magnetic resonance biomarker of systemic inflammation

Clinical Chemistry

Volumn 61, Issue 5, 2015, Pages 714-723

  Otvos, James D ^a   Shalaurova, Irina ^a   Wolak Dinsmore, Justyna ^a   Connelly, Margery A ^a   Mackey, Rachel H ^b   Stein, James H ^c   Tracy, Russell P ^d  

^a LABORATORY CORPORATION OF AMERICA   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; GLYCAN N ACETYLGLUCOSAMINE; HAPTOGLOBIN; INTERLEUKIN 6; OROSOMUCOID; TRANSFERRIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; N ACETYLGLUCOSAMINE; POLYSACCHARIDE;

ADULT; ALGORITHM; ANALYTIC METHOD; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GLYCOSYLATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE; PROTEIN ANALYSIS; PROTEIN DENATURATION; QUANTITATIVE ANALYSIS; SYSTEMIC INFLAMMATION; TRIACYLGLYCEROL BLOOD LEVEL; CHEMISTRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PROCEDURES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ACETYLGLUCOSAMINE; MAGNETIC RESONANCE SPECTROSCOPY; POLYSACCHARIDES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84929012744     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.232918     Document Type: Article

References (38)

1. Marth JD, Grewal PK. Mammalian glycosylation in immunity. Nat Rev Immunol 2008;8:874-87.
2. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
3. Gornik O, Lauc G. Glycosylation of serum proteins in inflammatory diseases. Dis Markers 2008;25:267-78.
4. Kushner I. Regulation of the acute phase response by cytokines. Perspect Biol Med 1993;36:611-22.
5. Dijk W, Turner G, Mackiewicz A. Changes in glycosylation of acute-phase proteins in health and disease: occurrence, regulation and function. Glycoconjugate J 1994;1:5-14.
6. Ceciliani F, Pocacqua V. The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Curr Protein Pept Sci 2007;8:91-108.
7. Packard RRS, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008;54:24-38.
8. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
9. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.
10. Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012;367:1310-20.
11. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SN, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Medicine 2008;5:e78.
12. Greenland P, Albert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2010;122:e584-636.
13. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-8.
14. deGoma EM, French B, Dunbar RL, Allison MA, Mohler ER III, Budoff MJ. Intraindividual variability of C-reactive protein: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2012;224:274-9.
15. Bell JD, Brown JC, Nicholson JK, Sadler PJ. Assignment of resonances for 'acute-phase' glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Lett 1987;215:311-5.
16. 1H NMR spectroscopy-based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients. J Proteome Res 2010;9:4545-53.
17. Kriat M, Vion-Dury J, Fayre R, Maraninchi D, Harle JR, Confort-Gouny S, et al. Variations of plasma sialic acid and N-acetylglucosamine levels in cancer, inflammatory diseases and bone marrow transplantation: a proton NMR spectroscopy study. Biochimie 1991;73:99-104.
18. Wurtz P, Makinen V-P, Soininen P, Kangas AJ, Tukiainen T, Kettunen J, et al. Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes 2012;61:1372-80.
19. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006;26:847-70.
20. Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein glycan biomarker and future cardiovascular disease. J Am Heart Assoc 2014;3:e001221.
21. Akinkuolie AO, Glynn RJ, Ridker PM, Mora S. Protein glycan side-chains, rosuvastatin therapy, and incident vascular events: an analysis from the JUPITER trial (Abstract). Circulation 2014;130:A17731.
22. Duprez D, Neuhaus J, Otvos J, Neaton JD, Lundgren JD. GlycA, a novel marker of inflammation, predicts cardiovascular events in HIC-positive patients: results of SMART study (Abstract). Circulation 2014;130:A14731.
23. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol 2002;156:871-81.
24. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007;192:211-7.
25. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.
26. 1H NMR spectroscopy and permethylation analysis. Biochemistry 1978;17:5206-14.
27. 1H nuclear magnetic resonance spectroscopy of sialyloligosaccharides for patients with sialidosis (mucolipidosis I and II). Eur J Biochem 1978;87:323-9.
28. Taniguchi T, Ishikawa Y, Tsunemitsu M, Fukuzake H. The structures of the asparagine-linked sugar chains of human apolipoprotein B-100. Arch Biochem Biophys 1989;273:197-205.
29. Fratzin H, Armstrong VW, Niehaus M, Hilschmann N, Seidel D. Structural relationship of an apolipoprotein (a) phenotype (570 kDa) to plasminogen: homologous kringle domains are linked by carbohydrate-rich regions. Biol Chem Hoppe-Seyler 1987;368:1533-44.
30. 13C labeling of the glycans. J Biomol NMR 1998;12:385-94.
31. Kettunen J, Tukiainen T, Sarin A-P, Ortega-Alonso A, Tikkanen E, Lyytikainen L-P, et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 2012;44:269-76.
32. Bock JL. NMR in clinical chemistry: where do we stand? Clin Chem 1994;40:1215-7.
33. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444-50.
34. Glynn RJ, MacFadyen JG, Ridker PM. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem 2009;55:305-12.
35. Clark GH, Fraser CG. Biological variation of acute phase proteins. Ann Clin Biochem 1993;30:373-6.
36. Bogaty P, Brophy JM, Boyer L, Simard S, Joseph L, et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 2005;165:221-6.
37. Bogaty P, Dagerais GR, Joseph L, Boyer L, Leblanc A, et al. Time variability of C-reactive protein: implications for clinical risk stratification. PLoS One 2013;8:e60759.
38. Koenig W, Sund M, Frohlich M, Lowel H, Hutchinson WL, et al. Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987. Am J Epidemiol 2003;158:357-64.